Professor Mark Kendall is the inventor of the Nanopatch, a needle-free vaccine delivery device which is under rapid research and development to product through spin-in company Vaxxas. Professor Kendall is a 2012 Rolex Laureate, recognising pioneering efforts to expand knowledge and improve human life. He co-founded Vaxxas with $15 million in capital investment - one of the largest investments in an Australian start-up biotechnology company. The Nanopatch technology has been licensed to US-based pharmaceutical company Merck & Co. Kendall's research group received the Eureka Prize for Research by an Interdisciplinary Team in 2011. Professor Kendall is an inaugural Australian Research Council Future Fellow.

Kendall has key international links spanning academia and industry including the University of Oxford, where he was a lecturer; Harvard; PATH; WHO; and the University of Washington. He is a member of a Scientific Advisory Group sponsored by the WHO that aims to fast-track the development of needle-free vaccine delivery technology for use in poor countries. His Nanopatch technology has been licensed to US-based pharmaceutical company Merck & Co. Kendall has lectured at the University of Oxford. While there, he was instrumental in building up PowderJect/PowderMed, which was sold to Pfizer for $400 million.

Kendall is the recipient of more than $40 million in competitive research funding and another $33 million from industry. He edits papers in the Journal of Nanotechnology and Shock Waves Journal. He is the inventor of 96 patents.

Kendall is a Rolex Laureate, recognizing pioneering efforts to expand knowledge and improve human life. He is the recipient of many prestigious accolades, including the The Australian Innovation Challenge in 2011. His AIBN group received the 2011 Eureka Prize for Interdisciplinary Research; and the Queensland Clinical Trial Network and Merck’s 2010 Translational Research Excellence Commercialisation Award. Professor Kendall won the Australian Society for Medical Research and Amgen’s Australia Medical Researcher Award in 2008; and was named Young Engineer of Britain 2004. He has presented at more than 90 international seminars and conferences, including the plenary at the 9th Symposium of the Lohmann Therapie-Systeme Academy (LTS) in Germany in 2012.

Health, Technology, Vaccines, Pharmaceutical, Innovation, Creativity, TED